XENE — Xenon Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $3.30bn
- $2.66bn
- 43
- 29
- 63
- 41
Annual cashflow statement for Xenon Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -41.6 | -28.8 | -78.9 | -125 | -182 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 3.06 | 6.44 | 11.1 | 26 | 28.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 33.5 | -26.1 | -2.65 | -0.676 | 5.63 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -4.71 | -48.1 | -69.5 | -98.4 | -145 |
| Capital Expenditures | -1.24 | -2.64 | -2.05 | -2.89 | -5.62 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -65 | -14.2 | -245 | -293 | -112 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -66.2 | -16.8 | -247 | -296 | -117 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 27.5 | 85.8 | 448 | 278 | 354 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -43 | 20.3 | 131 | -118 | 91.4 |